Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor

Drug Metabolism and Disposition

Volumn 24, Issue 10, 1996, Pages 1111-1120

  Lin, Jiunn H ^a   Chiba, Masato ^a   Balani, Suresh K ^a   Chen, I Wu ^a   Kwei, Gloria Y S ^a   Vastag, Kari J ^a   Nishime, Joy A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; CYTOCHROME P450 ISOENZYME; INDINAVIR; L 703943; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SPECIES DIFFERENCE;

ANIMALS; AREA UNDER CURVE; DOGS; HAPLORHINI; HIV PROTEASE INHIBITORS; INDINAVIR; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; HUMAN IMMUNODEFICIENCY VIRUS; MACACA MULATTA;

EID: 0029974065     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. J. R. Huff: HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 34, 2305-2314 (1991).
2. M. L. West, and D. P. Fairlie: Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol. Sci. 16, 67-75 (1995).
3. P. L. Darke, and J. R. Huff: HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol. 25, 399-454 (1994).
4. J. P. Vacca, B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. H. Lin, I-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff: L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91, 4096-4100 (1994).
5. D. Goon, and C. D. Klaassen: Dose-dependent intestinal glucuronidation and sulfation of acetaminophen in the rat in situ. J. Pharmacol. Exp. Ther. 252, 201-207 (1990).
6. W. H. Oldendorf: Brain uptake of radiolabeled amino acids, amines and hexoses after arterial injection. Am. J. Physiol. 221, 1629-1639 (1971).
7. J. H. Lin, I-W. Chen, and T-H. Lin: Blood-brain barrier permeability and in vivo activity of partial agonists of benzodiazepine receptor: a study of L-663,581 and its metabolites in rats. J. Pharmacol. Exp. Ther. 271, 1197-1202 (1994).
8. W. M. Pardridge, D. Crane, L. J. Mietus, and W. H. Oldendorf: Kinetics of regional blood-brain barrier transport and brain phosphorylation of glucose and 2-deoxyglucose in the barbiturate-anesthetized rats. J. Neurochem. 38, 1413-1418 (1982).
9. P. Tso, V. Pitts, and D. N. Granger: Role of lymph flow in chylomicron transport. Am. J. Physiol. 249, G21-25 (1985).
10. O. H. Lowry, N. J. Rosenbrough, A. L. Farr, and R. J. Randal: Protein measurement with Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
11. M. Chiba, M. Hensleigh, J. A. Nishime, S. K. Balani, and J. H. Lin: Role of cytochrome P-450 3A4 in human metabolism of MK-639, a potent HIV protease inhibitor. Drug Metab. Dispos., in press, 1996.
12. J. B. Houston: Utility of in vitro drug metabolism data in prediction of in vivo metabolic clearance. Biochem. Pharmacol. 47, 1469-1479 (1994).
13. H. Boxenbaum: Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. J. Pharmacokinet. Biopharm. 8, 165-176 (1980).
14. G. R. Wilkinson: Clearance approaches in pharmacology. Pharmacol. Rev. 39, 1-47 (1987).
15. J. H. Lin, Y. Sugiyama, S. Awazu, and M. Hanano: Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokinet. Biopharm. 10, 649-661 (1982).
16. R. L. Dedrick, D. S. Zaharko, and R. L. Lutz: Transport and binding of methotrexate in vivo. J. Pharm. Sci. 62, 882-890 (1973).
17. I-W. Chen, K. J. Vastag, and J. H. Lin: High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. J. Chromatogr. 672, 111-117 (1995).
18. M. Gibaldi, and D. Perrier: "Pharmacokinetics," 2nd ed. Marcel Dekker, New York, 1982.
19. M. L. Rocci, Jr., and W. J. Jusko: Lagran program for area and moments in pharmaceutical analysis. Comp. Prog. Biomed. 16, 203-216 (1983).
20. R. J. Tallarida, and R. B. Murray: "Manual of Pharmacological Calculation with Computer Program," 2nd ed. Springer-Verlag, New York, 1987.
21. S. K. Balani, B. H. Arison, L. Mathai, L. R. Kauffman, R. R. Miller, R. A. Stearns, I-W. Chen, and J. H. Lin: Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 23, 266-270 (1995).
22. F. P. Guengerich, and T. Shimada: Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4, 391-407 (1991).
23. J. H. Lin: Species similarities and differences in pharmacokinetics. Drug Metab. Dispos. 23, 1008-1021 (1995).
24. D. J. Clarke, and B. Burchell: The uridine diphosphate glucuronosyltransferase multigene family: function and regulation. In "Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity" (F. C. Kauffman, ed.), pp. 3-43. Springer-Verlag, New York, 1994.
25. B. Burchell, T. Ebner, R. Wooster, and L. Sutherland: Analysis of the specificity of human liver glucuronidation using cloned and stably expressed UDP-glucuronosyltransferase. In "Human Drug Metabolism" (E. H. Jeffrey, ed.), pp. 89-99. CRC Press, Boca Raton, 1992.
26. P. Dogterom: Development of a simple incubation system for metabolism studies with precision-cut liver slices. Drug Metab. Dispos. 21, 699-704 (1993).
27. M. Hanano, Y. Sawada, T. Iga, and Y. Sugiyama: The integration of in vitro data with physiological data. In "Topics in Pharmaceutical Science" (D. D. Brimer and P. Speiser, eds.), pp. 63-77. Elsevier Science Publisher, Amsterdam, 1987.
28. Y. Sugiyama, Y. Sawada, T. Iga, and M. Hanano: Reconstruction of in vivo metabolism from in vitro data. In "Xenobiotic Metabolism and Disposition" (R. Kato, R. W. Estabrook, and M. N. Cayen, eds.), pp. 225-235. Taylor & Francis, London, 1989.
29. M. Chiba, S. Fujita, and T. Suzuki: Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. J. Pharm. Sci. 79, 281-287 (1990).
30. J. H. Lin, M. Hayashi, S. Awazu, and M. Hanano: Correlation between in vitro and in vivo drug metabolism rate: oxidation of ethoxyphenzamide in rat. J. Pharmacokinet. Biopharm. 6, 327-337 (1978).
31. J. R. Gillette: Problems in correlating in vitro and in vivo studies of drug metabolism. In "Pharmacokinetics. A Modern View" (L. Z. Benet, G. Levy, and B. L. Ferraiole, eds.), pp. 235-252. Plenum Press, New York, 1984.
32. K. S. Pang, and M. Chiba: Metabolism: scaling-up from in vitro to organ and whole body. In "Handbook of Experimental Pharmacology" (P. G. Welling and L. P. Balant, eds.), vol. 110, pp. 101-187. Springer-Verlag, New York, 1994.